NYU LANGONE HEALTH
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 1841-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.nyulangone.org
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb
Completed
- Conditions
- Pulmonary TB
- Interventions
- Procedure: Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 10
- Registration Number
- NCT00212550
- Locations
- ๐บ๐ธ
NYU School of Medicine Division of Pulmonary and Critical Care, New York, New York, United States
Disease Modifying Genes in Severe Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 941
- Registration Number
- NCT00212537
- Locations
- ๐บ๐ธ
NYU School of Medicine, New York, New York, United States
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
Phase 2
Completed
- Conditions
- TuberculosisAIDS-related Complex
- Interventions
- Other: PlaceboDrug: Aerosol Interferon-GammaDrug: Subcutaneous interferon-gamma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 89
- Registration Number
- NCT00201123
- Locations
- ๐ฟ๐ฆ
The Lung Institute at University of Cape Town, Cape Town, South Africa
๐บ๐ธNYU School of Medicine, New York, New York, United States
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
Phase 1
Completed
- Conditions
- Hidradenitis Suppurativa
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 5
- Registration Number
- NCT00134134
- Locations
- ๐บ๐ธ
New York University School of Medicine, Dept of Dermatology, New York, New York, United States
Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Phase 4
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Behavioral: Individualized management of AD including caregiver training
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 20
- Registration Number
- NCT00120874
- Locations
- ๐บ๐ธ
Fisher Alzheimer's Program, New York University School of Medicine, New York, New York, United States
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
Completed
- Conditions
- Anxiety DisordersSeparation Anxiety DisorderPhobic Disorders
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 127
- Registration Number
- NCT00104195
- Locations
- ๐บ๐ธ
New York University's Child Study Center, New York, New York, United States
Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00004083
- Locations
- ๐บ๐ธ
Kaplan Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesPrecancerous ConditionUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 30
- Registration Number
- NCT00003331
- Locations
- ๐บ๐ธ
Kaplan Cancer Center, New York, New York, United States
Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 60
- Registration Number
- NCT00002619
- Locations
- ๐บ๐ธ
Kaplan Cancer Center, New York, New York, United States
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
Phase 2
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00004104
- Locations
- ๐บ๐ธ
Kaplan Cancer Center, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath